Associations - IDH2 mutation

IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	enasidenib Sensitive: A1 - Approval	enasidenib Sensitive: A1 - Approval
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: A2 - Guideline	venetoclax Sensitive: A2 - Guideline
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine Resistant: B - Late Trials	cytarabine Resistant: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide Sensitive: B - Late Trials	temozolomide Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	temozolomide gel Sensitive: B - Late Trials	temozolomide gel Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	PCV Sensitive: B - Late Trials	PCV Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + azacitidine Sensitive: B - Late Trials	venetoclax + azacitidine Sensitive: B - Late Trials
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	pamiparib Sensitive: C2 – Inclusion Criteria	pamiparib Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	dasatinib Sensitive: C2 – Inclusion Criteria	dasatinib Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Leukemia Leukemia	IDH2 mutation IDH2 mutation	Leukemia Leukemia	venetoclax Sensitive: C2 – Inclusion Criteria	venetoclax Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	IDH2 mutation IDH2 mutation	Myelodysplastic Syndrome MDS	enasidenib Sensitive: C2 – Inclusion Criteria	enasidenib Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	MEN-1703 Sensitive: C2 – Inclusion Criteria	MEN-1703 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	AG-881 Sensitive: C2 – Inclusion Criteria	AG-881 Sensitive: C2 – Inclusion Criteria
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	TG02 Sensitive: C3 – Early Trials	TG02 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials	cytarabine/daunorubicin liposomal formulation Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + enasidenib Sensitive: C3 – Early Trials	venetoclax + enasidenib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + RO5503781 Sensitive: C3 – Early Trials	venetoclax + RO5503781 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	IDH2 mutation IDH2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	copanlisib Sensitive: C3 – Early Trials	copanlisib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	IDH2 mutation IDH2 mutation	Chronic Myelomonocytic Leukemia CMML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + ABBV-621 Sensitive: C3 – Early Trials	venetoclax + ABBV-621 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	CFI-400945 Sensitive: C3 – Early Trials	CFI-400945 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + midostaurin Resistant: C3 – Early Trials	venetoclax + midostaurin Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + gilteritinib Resistant: C3 – Early Trials	venetoclax + gilteritinib Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	venetoclax + sorafenib Resistant: C3 – Early Trials	venetoclax + sorafenib Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Glioblastoma GBM	IDH2 mutation IDH2 mutation	Glioblastoma GBM	temozolomide gel Sensitive: C3 – Early Trials	temozolomide gel Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	IDH2 mutation IDH2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	IDH2 mutation IDH2 mutation	Anaplastic Astrocytoma Anaplastic Astrocytoma	PCV Sensitive: C3 – Early Trials	PCV Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Sarcoma Sarcoma	IDH2 mutation IDH2 mutation	Sarcoma Sarcoma	olaparib Sensitive: C3 – Early Trials	olaparib Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	7+3 (DAC) Sensitive: C3 – Early Trials	7+3 (DAC) Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine + clofarabine Sensitive: C3 – Early Trials	cytarabine + clofarabine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	cytarabine + cladribine Sensitive: C3 – Early Trials	cytarabine + cladribine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	decitabine + clofarabine Sensitive: C3 – Early Trials	decitabine + clofarabine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	decitabine + cladribine Sensitive: C3 – Early Trials	decitabine + cladribine Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Glioblastoma GBM	IDH2 mutation IDH2 mutation	Glioblastoma GBM	M7824 Sensitive: C3 – Early Trials	M7824 Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	IDH2 mutation IDH2 mutation	Acute Myelogenous Leukemia AML	CDIAG Sensitive: C3 – Early Trials	CDIAG Sensitive: C3 – Early Trials
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	AZD0530 Sensitive: D – Preclinical	AZD0530 Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	bosutinib Sensitive: D – Preclinical	bosutinib Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	IDH2 mutation IDH2 mutation	Cholangiocarcinoma Cholangiocarcinoma	ponatinib Sensitive: D – Preclinical	ponatinib Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	APO866 Sensitive: D – Preclinical	APO866 Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	NPI-0052 Sensitive: D – Preclinical	NPI-0052 Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	omacetaxine mepesuccinate Sensitive: D – Preclinical	omacetaxine mepesuccinate Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	regorafenib Sensitive: D – Preclinical	regorafenib Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	dactinomycin Sensitive: D – Preclinical	dactinomycin Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	romidepsin Sensitive: D – Preclinical	romidepsin Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	daunorubicin Sensitive: D – Preclinical	daunorubicin Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	teniposide Sensitive: D – Preclinical	teniposide Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	gemcitabine Sensitive: D – Preclinical	gemcitabine Sensitive: D – Preclinical
IDH2 mutation IDH2 mutation	Glioma Glioma	IDH2 mutation IDH2 mutation	Glioma Glioma	paclitaxel Sensitive: D – Preclinical	paclitaxel Sensitive: D – Preclinical